The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
LLM on par with head-and-neck subspecialists in analyzing MRI reports
September 16, 2026
DeVry, Pulse Radiology Institute launch MRI technology degree
September 15, 2026
Standardized care coordination may reduce inpatient MRI safety events
September 14, 2026



.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)

.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)











